These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30694085)

  • 21. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.
    Nyboe Andersen A; Nelson SM; Fauser BC; García-Velasco JA; Klein BM; Arce JC;
    Fertil Steril; 2017 Feb; 107(2):387-396.e4. PubMed ID: 27912901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by P. Barrière, S. Hamamah, E. Arbo, C. Avril, B. Salle, J.-L. Pouly, et al. (J Gynecol Obstet Hum Reprod. 2023;52(1):102510).
    Montenegro S; Helwig C; Schwarze JE; Castello-Bridoux C; Marque S; Lispi M; D'Hooghe T
    J Gynecol Obstet Hum Reprod; 2023 Oct; 52(8):102640. PubMed ID: 37549879
    [No Abstract]   [Full Text] [Related]  

  • 23. Biosimilar FSH preparations- are they identical twins or just siblings?
    Orvieto R; Seifer DB
    Reprod Biol Endocrinol; 2016 Jun; 14(1):32. PubMed ID: 27301324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone.
    Boostanfar R; Mannaerts B; Pang S; Fernandez-Sanchez M; Witjes H; Devroey P;
    Fertil Steril; 2012 Jun; 97(6):1351-8. PubMed ID: 22459628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap
    Winstel R; Wieland J; Gertz B; Mueller A; Allgaier H
    Drugs R D; 2017 Jun; 17(2):305-312. PubMed ID: 28386738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.
    Bocquet F; Paubel P; Fusier I; Cordonnier AL; Sinègre M; Le Pen C
    Appl Health Econ Health Policy; 2015 Feb; 13(1):47-59. PubMed ID: 25189295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pregnancy rates in varying age groups after in vitro fertilization: a comparison of follitropin alfa (Gonal F) and follitropin beta (Follistim).
    Williams RS; Vensel T; Sistrom CL; Kipersztok S; Rhoton-Vlasak A; Drury K
    Am J Obstet Gynecol; 2003 Aug; 189(2):342-6; discussion 346-7. PubMed ID: 14520188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
    Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of new quality standards of follitropin alfa on ovarian stimulation: meta-analysis of previous studies.
    Saz-Parkinson Z; López-Cuadrado T; Bouza C; Amate JM
    BioDrugs; 2009; 23(1):37-42. PubMed ID: 19344190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilar recombinant follicle stimulating hormones in infertility treatment.
    Santi D; Simoni M
    Expert Opin Biol Ther; 2014 Oct; 14(10):1399-409. PubMed ID: 24889801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corifollitropin alfa compared with follitropin beta in GnRH-antagonist ovarian stimulation protocols in an unselected population undergoing IVF/ICSI.
    Siristatidis C; Dafopoulos K; Christoforidis N; Anifandis G; Pergialiotis V; Papantoniou N
    Gynecol Endocrinol; 2017 Dec; 33(12):968-971. PubMed ID: 28508691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilars to recombinant human FSH medicines: comparable efficacy and safety to the original biologic.
    de Mora F; Fauser BCJM
    Reprod Biomed Online; 2017 Jul; 35(1):81-86. PubMed ID: 28462793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.
    Bocquet F; Paubel P; Fusier I; Cordonnier AL; Le Pen C; Sinègre M
    Appl Health Econ Health Policy; 2014 Jun; 12(3):315-26. PubMed ID: 24578185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Biosimilars: assessment of efficacy, safety and cost].
    Domínguez-Gil Hurlé A
    Farm Hosp; 2010 Mar; 34 Suppl 1():25-8. PubMed ID: 20920855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome.
    Bonduelle M; Mannaerts B; Leader A; Bergh C; Passier D; Devroey P
    Hum Reprod; 2012 Jul; 27(7):2177-85. PubMed ID: 22587997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol.
    Salgueiro LL; Rolim JR; Moura BR; Machado SP; Haddad C
    JBRA Assist Reprod; 2016 Aug; 20(3):123-6. PubMed ID: 27584604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.